NDAORALSUSPENSION
Approved
Apr 2016
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
6/8 — Strong
FYCOMPA (perampanel) by Catalyst Pharmaceuticals is ampa receptor antagonists [moa]. Approved for epilepsy, partial-onset seizures, generalized tonic-clonic seizures and 1 more indications. First approved in 2016.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FYCOMPA (perampanel) is an oral noncompetitive AMPA glutamate receptor antagonist approved for epilepsy in patients with partial-onset and generalized tonic-clonic seizures. It is available as a suspension formulation and works by blocking AMPA receptors to reduce seizure activity. The drug is indicated for refractory partial seizures and represents a unique mechanism within the antiepileptic drug class.
LOE Approaching2mo to LOE
With LOE approaching in July 2026 and current spending of $72M annually, the brand is transitioning into a defensive posture requiring smaller, focused medical affairs and patient access teams.
Mechanism of Action
AMPA Receptor Antagonists
Pharmacologic Class:
Noncompetitive AMPA Glutamate Receptor Antagonist
Indications (4)
Worked on FYCOMPA at Catalyst Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.